Evidence map›Paper›PMID 37653175›Full record

ArticleThe protein journal2023

Production and Purification of Cysteine-Rich Leptospiral Virulence-Modifying Proteins with or Without mCherry Fusion.

Reetika Chaurasia, Cathleen Liang, Kenneth How, Dielson S Vieira, Joseph M Vinetz

Abstract read
PubMed Publisher
In one paragraph

Article in The protein journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Reetika ChaurasiaSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. reetika.chaurasia@yale.edu.
Cathleen LiangSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Kenneth HowSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Dielson S VieiraSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Joseph M VinetzSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. joseph.vinetz@yale.edu.
Yale University · US

Funding

Predicting Risk of Human Leptospiros by Environmental SurveillanceR01AI108276 · NIAID · YALE UNIVERSITY · PI VINETZ, JOSEPH M. · 2013 to 2017
$3.6M
Americas Foundation 4030-20National Institute of Allergy and Infectious Diseases R01AI108276
6 · The paper itself

Abstract

Recombinant fluorescent fusion proteins are fundamental to advancing many aspects of protein science. Such proteins are typically used to enable the visualization of functional proteins in experimental systems, particularly cell biology. An important problem in biotechnology is the production of functional, soluble proteins. Here we report the use of mCherry-fusions of soluble, cysteine-rich, Leptospira-secreted exotoxins in the PF07598 gene family, the so-called virulence modifying (VM) proteins. The mCherry fusion proteins facilitated the visual detection of pink colonies of the VM proteins (LA3490 and LA1402) and following them through lysis and sequential chromatography steps. CD-spectroscopy analysis confirmed the stability and robustness of the mCherry-fusion protein, with a structure comparable to AlphaFold structural predictions. LA0591, a unique member of the PF07598 gene family that lacks N-terminal ricin B-like domains, was produced without mCherry tag that strengthens the recombinant protein production protocol without fusion protein as well. The current study provides the approaches for the synthesis of 50-125 kDa soluble, cysteine-rich, high-quality fast protein liquid chromatography (FPLC)-purified protein, with and without a mCherry tag. The use of mCherry-fusion proteins enables a streamlined, efficient process of protein production and qualitative and quantitative downstream analytical and functional studies. Approaches for troubleshooting and optimization were evaluated to overcome difficulties in recombinant protein expression and purification, demonstrating biotechnology utility in accelerating recombinant protein production.

Indexed as

Bacterial ProteinsLeptospiraLuminescent ProteinsRecombinant Fusion ProteinsVirulence FactorsCysteineEscherichia coliRed Fluorescent ProteinBacterial ProteinsCysteineLuminescent ProteinsRecombinant Fusion ProteinsRed Fluorescent ProteinVirulence FactorsFluorescence intensitymCherryPF07598 gene familySoluble proteinVM proteins

Identifiers

PMID37653175
OpenAlexW4386319046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.